uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms
Meiji Pharmaceut Univ, Dept Biopharmaceut, Noshio 2-522-1, Tokyo, Japan..
Meiji Pharmaceut Univ, Dept Biopharmaceut, Noshio 2-522-1, Tokyo, Japan..
Meiji Pharmaceut Univ, Dept Biopharmaceut, Noshio 2-522-1, Tokyo, Japan..
Univ Florida, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA.;Univ Florida, Ctr Pharmacogen, Gainesville, FL USA..
Show others and affiliations
2017 (English)In: The Pharmacogenomics Journal, ISSN 1470-269X, E-ISSN 1473-1150, Vol. 17, no 6, p. 494-500Article in journal (Refereed) Published
Abstract [en]

Using population pharmacokinetic analysis (PPK), we attempted to identify predictors of S-warfarin clearance (CL(S)) and to clarify population differences in S-warfarin pharmacokinetics among a cohort of 378 African American, Asian and white patients. Significant predictors of CL(S) included clinical (age, body weight and sex) and genotypic (CYP2C9*2,*3 and *8) factors, as well as African American ethnicity, the median CL(S) being 30% lower in the latter than in Asians and whites (170 versus 243 and 250 ml h(-1), P<0.01). The plasma S-warfarin (Cp(S)) time courses following the genotype-based dosing algorithms simulated using the PPK estimates showed African Americans with CYP2C9*1/*1 and any of the VKORC1 genotypes would have an average Cp(S) at steady state 1.5-1.8 times higher than in Asians and whites. These results indicate warfarin dosing algorithms should be evaluated in each respective ethnic population. Further study of a large African American cohort will be necessary to confirm the present findings.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP , 2017. Vol. 17, no 6, p. 494-500
National Category
Genetics Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-343565DOI: 10.1038/tpj.2016.57ISI: 000416407400004OAI: oai:DiVA.org:uu-343565DiVA, id: diva2:1187017
Available from: 2018-03-02 Created: 2018-03-02 Last updated: 2018-03-02Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Scordo, Gabriella Maria

Search in DiVA

By author/editor
Scordo, Gabriella Maria
By organisation
Clinical pharmacogenomics and osteoporosis
In the same journal
The Pharmacogenomics Journal
GeneticsPharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf